Practical aspects of treatment with drotrecogin alfa (activated)

Critical Care

Volumn 11, Issue SUPPL. 5, 2007, Pages

  Camporota, Luigi ^a   Wyncoll, Duncan ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DROTRECOGIN; HEPARIN; PLACEBO; PROTEIN C; PROTHROMBIN; THROMBOPLASTIN; WARFARIN; ANTIINFECTIVE AGENT; RECOMBINANT PROTEIN;

APACHE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EARLY INTERVENTION; EPIDEMIC MENINGITIS; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTENSIVE CARE; KIDNEY FAILURE; MEDICAL DECISION MAKING; MORTALITY; MULTIPLE ORGAN FAILURE; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PATIENT SELECTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEPSIS; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; SURGICAL PATIENT; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS; ADULT; AGED; ANAPHYLACTOID PURPURA; CHILD; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG INTERACTION; ECONOMICS; EUROPEAN UNION; MENINGITIS; MENINGOCOCCOSIS; PRACTICE GUIDELINE;

ADULT; AGED; ANTI-INFECTIVE AGENTS; APACHE; ASPIRIN; CHILD; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EUROPEAN UNION; HEPARIN; HUMANS; MENINGITIS; MENINGOCOCCAL INFECTIONS; MULTIPLE ORGAN FAILURE; PANCREATITIS; PRACTICE GUIDELINES AS TOPIC; PROTEIN C; PURPURA, SCHOENLEIN-HENOCH; RECOMBINANT PROTEINS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; UNITED STATES; WARFARIN;

EID: 40649122773     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6158     Document Type: Review

References (59)

1. Vincent JL Sakr Y Sprung CL Ranieri VM Reinhart K Gerlach H Moreno R Carlet J Le Gall JR Payen D Sepsis in European intensive care units: results of the SOAP study Crit Care Med 2006, 34:344-353 10.1097/ 01.CCM.0000194725.48928.3A 16424713
2. Alberti C Brun-Buisson C Burchardi H Martin C Goodman S Artigas A Sicignano A Palazzo M Moreno R Boulme R Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study Intensive Care Med 2002, 28:108-121 10.1007/s00134-001-1143-z 11907653
3. Harrison DA Welch CA Eddleston JM The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: Secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database Crit Care 2006, 10:R42 1550902 16542492 10.1186/cc4854
4. Dellinger RP Carlet JM Masur H Gerlach H Calandra T Cohen J Gea-Banacloche J Keh D Marshall JC Parker MM Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock Intensive Care Med 2004, 30:536-555 10.1007/s00134-004-2398-y 14997291
5. Ely EW Laterre PF Angus DC Helterbrand JD Levy H Dhainaut JF Vincent JL Macias WL Bernard GR Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 2003, 31:12-19 10.1097/00003246-200301000-00002 12544987
6. Rice TW Bernard GR Therapeutic intervention and targets for sepsis Annu Rev Med 2005, 56:225-248 10.1146/annurev.med.56.082103.104356 15660511
7. Bernard GR Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis Crit Care Med 2003, (Suppl):S85-S93 10.1097/00003246-200301001-00012
8. Annane D Bellissant E Cavaillon JM Septic shock Lancet 2005, 365:63-78 10.1016/S0140-6736(04)17667-8 15639681
9. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709 10.1056/NEJM200103083441001 11236773
10. Yan SB Helterbrand JD Hartman DL Wright TJ Bernard GR Low levels of protein C are associated with poor outcome in severe sepsis Chest 2001, 120:915-922 10.1378/chest.120.3.915 11555529
11. Mesters RM Helterbrand J Utterback BG Yan B Chao YB Fernandez JA Griffin JH Hartman DL Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications Crit Care Med 2000, 28:2209-2216 10.1097/00003246-200007000-00005 10921542
12. Dhainaut JF Laterre PF Janes JM Bernard GR Artigas A Bakker J Riess H Basson BR Charpentier J Utterback BG Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial Intensive Care Med 2003, 29:894-903 12712239
13. Laterre PF Wittebole X Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis: Practical aspects at the bedside and patient identification Crit Care 2003, 7:445-450 374360 14624684 10.1186/cc2342
14. Drotrecogin alpha (activated) for severe sepsis http://www.nice.org.uk/ TA084guidance
15. Angus DC Laterre PF Helterbrand J Ely EW Ball DE Garg R Weissfeld LA Bernard GR The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis Crit Care Med 2004, 32:2199-2206 10.1097/ 01.CCM.0000114816.62331.08 15640631
16. Abraham E Laterre PF Garg R Levy H Talwar D Trzaskoma BL Francois B Guy JS Bruckmann M Rea-Neto A Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 2005, 353:1332-1341 10.1056/NEJMoa050935 16192478
17. Nadel S Goldstein B Williams MD Dalton H Peters M Macias WL Abd-Allah SA Levy H Angle R Wang D Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial Lancet 2007, 369:836-843 10.1016/S0140-6736(07)60411-5 17350452
18. Levi M Levy M Williams MD Douglas I Artigas A Antonelli M Wyncoll D Janes J Booth FV Wang D Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated) Am J Respir Crit Care Med 2007, 176:483-490 10.1164/rccm.200612-1803OC 17556722
19. Vincent JL Bernard GR Beale R Doig C Putensen C Dhainaut JF Artigas A Fumagalli R Macias W Wright T Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment Crit Care Med 2005, 33:2266-2277 10.1097/01.CCM.0000181729.46010.83 16215381
20. Beale R Brunkhorst F Martin G Williams M Nelson D Janes J Severe sepsis and drotrecogin alfa (activated) use: Results from the PROGRESS registry [abstract] Crit Care 2007, 11(Suppl 2):P64 10.1186/cc5224
21. Rowan K Welch CA North E Harrison DA Multicentre Audit on the use of Drotrecogin alfa (activated) in United Kingdom Critical Care Units [abstract] Crit Care 2007, 11(Suppl 2):P56 10.1186/cc5216
22. Kubler A Mayzner-Zawadzka E Durek G Gaszynski W Karpel E Mikaszewska-Sokolewicz M Majak P Results of severe sepsis treatment program using recombinant human activated protein C in Poland Med Sci Monit 2006, 12:CR107-CR112 16501420
23. Spriet I Meersseman W Wilmer A Meyfroidt G Casteels M Willems L Evaluation of drotrecogin alpha use in a Belgian university hospital Pharm World Sci 2006, 28:290-295 10.1007/s11096-006-9045-3 17111246
24. Vincent J Laterre P Janes J Nelson D Haentjens T Sartral M Ermens M Sundin D Analysis of drotrecogin alfa (activated) use in Belgium: Comparison to PROGRESS registry data [abstract] Intensive Care Med 2005, 31(Suppl 1):A0911
25. Bertolini G Rossi C Anghileri A Livigni S Addis A Poole D Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey Intensive Care Med 2007, 33:426-434 10.1007/s00134-007-0554-x 17325836
26. Laterre PF Levy H Clermont G Ball DE Garg R Nelson DR Dhainaut JF Angus DC Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial Crit Care Med 2004, 32:2207-2218 15640632
27. Wyncoll D Clinical experience with xigris [in French] Ann Fr Anesth Reanim 2003, 22(Spec No 1):46-47 15359944
28. Vincent JL Organ dysfunction in patients with severe sepsis Surg Infect (Larchmt) 2006, 7(Suppl 2):S69-S72 16895511
29. Vincent JL Ferreira F Moreno R Scoring systems for assessing organ dysfunction and survival Crit Care Clin 2000, 16:353-366 10.1016/ S0749-0704(05)70114-7 10768086
30. Russell JA Singer J Bernard GR Wheeler A Fulkerson W Hudson L Schein R Summer W Wright P Walley KR Changing pattern of organ dysfunction in early human sepsis is related to mortality Crit Care Med 2000, 28:3405-3411 10.1097/00003246-200010000-00005 11057793
31. Ferreira FL Bota DP Bross A Melot C Vincent JL Serial evaluation of the SOFA score to predict outcome in critically ill patients JAMA 2001, 286:1754-1758 10.1001/jama.286.14.1754 11594901
32. Levy MM Macias WL Vincent JL Russell JA Silva E Trzaskoma B Williams MD Early changes in organ function predict eventual survival in severe sepsis Crit Care Med 2005, 33:2194-2201 10.1097/ 01.CCM.0000182798.39709.84 16215369
33. Shorr AF Bernard GR Dhainaut JF Russell JR Macias WL Nelson DR Sundin DP Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome Crit Care 2006, 10:R92 1550956 16780598 10.1186/cc4946
34. Ely EW Angus DC Williams MD Bates B Qualy R Bernard GR Drotrecogin alfa (activated) treatment of older patients with severe sepsis Clin Infect Dis 2003, 37:187-195 10.1086/375775 12856210
35. Laterre PF Garber G Levy H Wunderink R Kinasewitz GT Sollet JP Maki DG Bates B Yan SC Dhainaut JF Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study Crit Care Med 2005, 33:952-961 10.1097/01.CCM.0000162381.24074.D7 15891319
36. Vincent JL Nadel S Kutsogiannis DJ Gibney RT Yan SB Wyss VL Bailey JE Mitchell CL Sarwat S Shinall SM Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: A retrospective analysis of patients enrolled in recent clinical studies Crit Care 2005, 9:R331-R343 1269439 16137345 10.1186/cc3538
37. Barie PS Williams MD McCollam JS Bates BM Qualy RL Lowry SF Fry DE Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis Am J Surg 2004, 188:212-220 10.1016/ j.amjsurg.2004.06.008 15450822
38. Barie PS Hydo LJ Shou J Eachempati SR Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis Surg Infect (Larchmt) 2006, 7(Suppl 2):S77-S80 16895513
39. Nathens AB Curtis JR Beale RJ Cook DJ Moreno RP Romand JA Skerrett SJ Stapleton RD Ware LB Waldmann CS Management of the critically ill patient with severe acute pancreatitis Crit Care Med 2004, 32:2524-2536 10.1097/01.CCM.0000148222.09869.92 15599161
40. Machala W Wachowicz N Komorowska A Gaszynski W The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis: Two case studies Med Sci Monit 2004, 10:CS31-CS36 15232511
41. Jamdar S Siriwardena AK Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis Crit Care 2005, 9:321-322 1269478 16137370 10.1186/cc3777
42. Dhainaut JF Yan SB Joyce DE Pettila V Basson B Brandt JT Sundin DP Levi M Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation J Thromb Haemost 2004, 2:1924-1933 10.1111/ j.1538-7836.2004.00955.x 15550023
43. Implement the Sepsis Management Bundle: Administer Drotrecogin Alfa (Activated) by a Standard Policy http://www.ihi.org/IHI/Topics/ CriticalCare/Sepsis/Changes/IndividualChanges/ AdministerDrotrecoginAlfaActivatedbyaStandardPolicy.htm
44. Rivers E Nguyen B Havstad S Ressler J Muzzin A Knoblich B Peterson E Tomlanovich M Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 2001, 345:1368-1377 10.1056/ NEJMoa010307 11794169
45. Vincent JL O'Brien J Jr Wheeler A Wittebole X Garg R Trzaskoma BL Sundin DP Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis Crit Care 2006, 10:R74 1550949 16684364 10.1186/cc4909
46. Choi G de Pont AC Schultz MJ Timing of drotrecogin alfa (activated) treatment in severe sepsis Crit Care 2006, 10:419 author reply 419 1750968 16934134 10.1186/cc5010
47. Steingrub J Sanchez P Zeckel M Bates B Qualy R Safety of drotrecogin alfa (activated): Results of MERCURY, a retrospective multicenter observation study [abstract] Crit Care Med 2003, 31:A117
48. Kanji S Perreault MM Chant C Williamson D Burry L Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study Intensive Care Med 2007, 33:517-523 10.1007/s00134-007-0555-9 17325837
49. Macias WL Vallet B Bernard GR Vincent JL Laterre PF Nelson DR Derchak PA Dhainaut JF Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis Crit Care Med 2004, 32:2385-2391 10.1097/ 01.CCM.0000147440.71142.AC 15599140
50. Machiavello L Ellis G Bowden S Smithies M A large, single-centre UK registry of drotrecogin alfa-activated use [abstract] Crit Care 2007, 11(Suppl 2):P58 10.1186/cc5218
51. Dries D Awad S Woodward B Wang D Williams M Surgical patients from the XPRESS study: Prophylactic heparin in severe sepsis patients receiving Drotrecogin Alfa (activated) [abstract] Crit Care Med 2006, 34:A100 10.1097/00003246-200612002-00347
52. Macias WL Dhainaut JF Yan SC Helterbrand JD Seger M Johnson G III Small DS Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis Clin Pharmacol Ther 2002, 72:391-402 10.1067/mcp.2002.128148 12386641
53. de Pont AC Bouman CS de Jonge E Vroom MB Buller HR Levi M Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis Intensive Care Med 2003, 29:1205 10.1007/ s00134-003-1781-4 12761613
54. Uchino S Fealy N Baldwin I Morimatsu H Bellomo R Continuous venovenous hemofiltration without anticoagulation ASAIO J 2004 50 76-80 10.1097/ 01.MAT.0000104822.30759.A7 14763495
55. Oudemans-van Straaten HM Wester JP de Pont AC Schetz MR Anticoagulation strategies in continuous renal replacement therapy: Can the choice be evidence based? Intensive Care Med 2006, 32:188-202 10.1007/ s00134-005-0044-y 16453140
56. Monchi M Berghmans D Ledoux D Canivet JL Dubois B Damas P Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study Intensive Care Med 2004, 30:260-265 10.1007/ s00134-003-2047-x 14600809
57. Levi M Levy M Williams M Janes J Wang D Macias W Abrupt withdrawal of prophylactic heparin in severe sepsis: Possible rebound thrombosis [abstract] Intensive Care Med 2006, 32:A376
58. Green C Dinnes J Takeda A Shepherd J Hartwell D Cave C Payne E Cuthbertson BH Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: A systematic review and economic evaluation Health Technol Assess 2005, 9:1-126 iii-iv 15774234
59. Riou Franca L Launois R Le Lay K Aegerter P Bouhassira M Meshaka P Guidet B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Int J Technol Assess Health Care 2006, 22:101-108 16673686